Abstract
Background Treatment for complex multifactorial neurological disorders may benefit more from multifunctional chemicals. Dysregulation of monoaminergic pathways and neuroinflammation are typical confluence points in a range of neuropsychiatric and neurodegenerative illnesses. Polypharmacological medications that affect neuroinflammatory and monoaminergic pathways were investigated as potential targets for these diseases. The aim of this study was to investigate the in vitro and in silico multi-target neuroprotective activity of Khaya grandifololia . Methods Decoction and hydro-ethanolic extracts were prepared and screened for their ability to inhibit enzymes related to inflammation (15-lipoxygenase, LOX), neurodegeneration (monoamine oxidase, MAO), and protein glycation and fibrillation using enzymological fluorimetric assays and docking simulations. Results All extracts were able to strongly inhibit the activity of MAO as well as the glycation and fibrillation activities. Also, these extracts moderately inhibited 15-LOX activity. Conclusion These results extend the knowledge on the potential use of Khaya grandifololia to combat multifactorial disorders, giving new approaches into therapeutic avenues for neurodegenerative disease such as Alzheimer's disease.